![Overall Response Rate in Previously Untreated CLL | CALQUENCE® (acalabrutinib) 100 mg tablets | For HCPs Overall Response Rate in Previously Untreated CLL | CALQUENCE® (acalabrutinib) 100 mg tablets | For HCPs](https://www.calquencehcp.com/content/dam/open-digital/hcp-cal/us/en/cll/cll-mobile/calquence-overall-response-rate-chart.png)
Overall Response Rate in Previously Untreated CLL | CALQUENCE® (acalabrutinib) 100 mg tablets | For HCPs
![Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non–Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses | Journal of Clinical Oncology Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non–Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses | Journal of Clinical Oncology](https://ascopubs.org/cms/10.1200/JCO.2014.59.0489/asset/images/zlj9991050600002.jpeg)
Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non–Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses | Journal of Clinical Oncology
![Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study - Journal of Hepatology Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study - Journal of Hepatology](https://www.journal-of-hepatology.eu/cms/asset/734a0236-aae1-490d-bbfe-b8cf04ab02e7/ga1.jpg)
Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study - Journal of Hepatology
![Table 3 from New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). | Semantic Scholar Table 3 from New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/871ed6d95d395e93dce6e1cb05a39f498296c910/8-Table3-1.png)
Table 3 from New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). | Semantic Scholar
![Objective response rate of placebo in randomized controlled trials of anticancer medicines - eClinicalMedicine Objective response rate of placebo in randomized controlled trials of anticancer medicines - eClinicalMedicine](https://www.thelancet.com/cms/attachment/85ef883b-0cb0-44dc-ad95-d2c19f552c25/gr1.jpg)
Objective response rate of placebo in randomized controlled trials of anticancer medicines - eClinicalMedicine
![Investigator-assessed confirmed objective response rate (per RECIST),... | Download Scientific Diagram Investigator-assessed confirmed objective response rate (per RECIST),... | Download Scientific Diagram](https://www.researchgate.net/publication/337017829/figure/tbl1/AS:821688686104596@1572917257715/Investigator-assessed-confirmed-objective-response-rate-per-RECIST-duration-of_Q320.jpg)